The proportion of employers offering these medications tends to increase as employer increases in size as well, with KFFs data indicating that about 16% of employers that have between 200 and 999 employees offering semaglutide and/or other GLP-1 coverage for weight loss, while 24% of employers with between 1,000 and 4,999 employees cover these prescriptions, and 25% of employers that have 5,000 or more employees do so
- Anti-Aging: Shows potential in tissue regeneration and health
Running multiple consecutive cycles costs less per cycle than running single cycles, because the fixed costs of protocol design and initial preparation are spread across more treatment

Tesamorelin Recommended for body recomposition Pros Has been shown to selectively reduce abdominal fat in patients with HIV Can also increase muscle area and strength Promising implications for cognitive and cardiovascular health No reported risk of immunogenicity Cons Studies so far have focused on patients with HIV May cause flu-like symptoms Usually administered by subcutaneous injection Prohibited by the World Anti-Doping Agency Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy excess abdominal lipid accumulation as a result of antiretroviral therapy its efficacy against which was evidenced in a 2010 clinical trial that demonstrated an 18% decrease in visceral fat in intervention subjects compared to placebo.11 Concerning muscle growth, a later study of HIV patients determined that tesamorelin was effective in increasing skeletal muscle area and density.28 Also, because visceral fat is associated with increased cardiovascular mortality, tesamorelin exhibits promise as a treatment for serious health conditions like heart disease and stroke.37 Although tesamorelin studies so far have understandably centered on patients with HIV, theory holds that the peptide should have the same effects on other users
